Xilio Therapeutics (XLO) Net Cash Flow (2020 - 2026)
Xilio Therapeutics (XLO) posted Net Cash Flow of $12.8 million for Q1 2026, down 62.08% sequentially from $33.8 million in Q4 2025, and down 62.09% YoY from $33.8 million in Q1 2025.
Xilio Therapeutics (XLO) Net Cash Flow (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Net Cash Flow for 7 years, with the latest figure at $12.8 million in Q1 2026.
- Quarterly Net Cash Flow fell 62.09% year-over-year to $12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.3 million (up 13.2% YoY) and the FY2025 annual result came in at $82.3 million, up 662.98% from the prior year.
- Net Cash Flow declined to $12.8 million in Q1 2026 per XLO's latest filing, from $33.8 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $40.0 million in Q2 2024 and troughed at -$27.1 million in Q1 2023.
- A 5-year average of -$2.8 million and a median of -$15.1 million in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow sank 119.08% in 2022, then surged 666.57% in 2025.
- Over 5 years, Net Cash Flow stood at -$18.8 million in 2022, then gained by 19.69% to -$15.1 million in 2023, then surged by 60.42% to -$6.0 million in 2024, then soared by 666.57% to $33.8 million in 2025, then tumbled by 62.08% to $12.8 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $12.8 million, $33.8 million, and -$17.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | -14.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.29 Mn |
| Jun 30, 2026 | -14.29 Mn |
| Mar 31, 2026 | 12.81 Mn |
| Mar 31, 2026 | 12.81 Mn |
| Dec 31, 2025 | 33.77 Mn |
| Dec 31, 2025 | 33.77 Mn |
| Sep 30, 2025 | -17.78 Mn |
| Sep 30, 2025 | -17.78 Mn |
| Jun 30, 2025 | 32.48 Mn |
| Jun 30, 2025 | 32.48 Mn |
| Mar 31, 2025 | 33.79 Mn |
| Mar 31, 2025 | 33.79 Mn |
| Dec 31, 2024 | -5.96 Mn |
| Dec 31, 2024 | -5.96 Mn |
| Sep 30, 2024 | -13.68 Mn |
| Sep 30, 2024 | -13.68 Mn |
| Jun 30, 2024 | 40.00 Mn |
| Jun 30, 2024 | 40.00 Mn |
| Mar 31, 2024 | -9.55 Mn |
| Mar 31, 2024 | -9.55 Mn |